- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07703436
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib (confirmed by Blinded Independent Central Review [BICR] per modified Response Assessment in Neuro-Oncology [RANO] 2.0), and are not in need of immediate chemotherapy or radiotherapy.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Clinical Trials at Nuvation Bio
- Telefonnummer: 332-208-6102
- E-post: ClinicalTrials@nuvationbio.com
Studieorter
-
-
California
-
Los Angeles, California, Förenta staterna, 90095
- Har inte rekryterat ännu
- University of California, Los Angeles
-
Huvudutredare:
- Robert Chong, MD
-
Kontakt:
- Quan Li
- Telefonnummer: 310-825-1416
- E-post: quanli@mednet.ucla.edu
-
San Francisco, California, Förenta staterna, 94143
- Har inte rekryterat ännu
- University of California, San Francisco
-
Huvudutredare:
- John De Groot, MD
-
Kontakt:
- Neuro Onc New Patient Coordinator
- Telefonnummer: 415-353-2193
- E-post: neurooncnewpatientcoord@ucsf.edu
-
-
Connecticut
-
New Haven, Connecticut, Förenta staterna, 06510
- Har inte rekryterat ännu
- Yale University
-
Huvudutredare:
- Nicholas Blondin, MD
-
Kontakt:
- Amy Rodrigues
- E-post: amy.rodrigues@yale.edu
-
Kontakt:
- E-post: cto-neuro@yale.edu
-
-
Florida
-
Miami, Florida, Förenta staterna, 33136
- Har inte rekryterat ännu
- University of Miami Health
-
Kontakt:
- Leonela Wright
- Telefonnummer: 305-243-0864
- E-post: lxw612@med.miami.edu
-
Huvudutredare:
- Juan Blaquier, MD
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 46202
- Rekrytering
- Indiana University
-
Huvudutredare:
- Kathryn Nevel, MD
-
Kontakt:
- NeuroOncology Clinical Trials
- Telefonnummer: 3179634823
- E-post: neuroct@iu.edu
-
-
Louisiana
-
New Orleans, Louisiana, Förenta staterna, 70112
- Har inte rekryterat ännu
- LSU LCMC Health Cancer Center
-
Huvudutredare:
- Yazmin Odia, MD
-
Kontakt:
- Yazmin Odia
- Telefonnummer: (646) 634-9655
- E-post: yodia@lsuhsc.edu
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02214
- Har inte rekryterat ännu
- Massachusetts General Hospital
-
Kontakt:
- Vihang Nakhate
- Telefonnummer: 617-724-8770
- E-post: vnakhate@mgh.harvard.edu
-
Huvudutredare:
- Vihang Nakhate, MD
-
-
New Jersey
-
New Brunswick, New Jersey, Förenta staterna, 08901
- Har inte rekryterat ännu
- Rutgers Cancer Institute
-
Huvudutredare:
- Morana Vojnic, MD
-
Kontakt:
- Kasie Diorio
- Telefonnummer: 732-235-2465
- E-post: kassie.diorio@rutgers.edu
-
-
New York
-
New York, New York, Förenta staterna, 10016
- Rekrytering
- NYU Langone Health
-
Kontakt:
- Jose McFaline-Figueroa, MD
- Telefonnummer: 212-731-6267
- E-post: Jose.McFalineFigueroa@nyulangone.org
-
New York, New York, Förenta staterna, 10032
- Har inte rekryterat ännu
- Columbia University Medical Center
-
Huvudutredare:
- Andrew Lassman, MD
-
Kontakt:
- Research Nurse Navigator
- Telefonnummer: 212-342-5162
- E-post: Cancerclinicaltrials@cumc.columbia.edu
-
-
Ohio
-
Cleveland, Ohio, Förenta staterna, 44106
- Har inte rekryterat ännu
- Cleveland Clinic
-
Huvudutredare:
- Mina Lobbous, MD
-
Kontakt:
- Marci Ciolfi
- Telefonnummer: 216-445-3307
- E-post: ciolfim@ccf.org
-
Columbus, Ohio, Förenta staterna, 43210
- Har inte rekryterat ännu
- The Ohio State University Comprehensive Cancer Center
-
Kontakt:
- Pierre Giglio
- Telefonnummer: 614-293-4448
- E-post: Pierre.Giglio@osumc.edu
-
Huvudutredare:
- Pierre Giglio, MD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria:
- Histologically confirmed Grade 2 or 3 IDH-mutant astrocytoma or IDH-mutant and 1p19q co-deleted oligodendroglioma, according to WHO CNS 2021 criteria
- IDH1 mutation (e.g., R132H/C/G/S/L) based on immunohistochemistry (IHC) (R132H only), PCR, or next generation sequencing (NGS).
- Have had at least 1 prior surgery for glioma (biopsy, sub-total resection, or gross total resection).
- Measurable disease per modified RANO 2.0 confirmed by BICR during Screening.
- Previously treated with vorasidenib and experienced radiographic disease progression during treatment and are not in need of immediate chemotherapy or radiotherapy in the opinion of the Investigator. Disease progression must be confirmed by BICR using modified RANO 2.0.
- Adequate hematologic and organ function
- Expected survival of ≥12 months
Key Exclusion Criteria:
- Any prior anticancer therapy other than surgery (biopsy, sub-total, or gross total resection) and vorasidenib for treatment of glioma.
- Discontinued vorasidenib for toxicity or any reason other than radiographic disease progression
- Prior treatment with anti-angiogenic agents such as Avastin (bevacizumab) or investigational agents for glioma.
- Brainstem or spinal cord involvement either as primary location, site of multifocal involvement, or by significant tumor extension.
- Significant functional or neurocognitive deficits, including uncontrolled seizures
- Evidence of leptomeningeal disease.
- Use of therapeutic doses of steroids for signs/symptoms of glioma. Participants taking physiologic doses (defined as equivalent of <1.5 mg of dexamethasone equivalent) for medical conditions not related to glioma will be permitted.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Safusidenib
Safusidenib 250 mg BID |
Safusidenib administered twice daily as a single agent orally on Days 1 to 28 of a 28-day cycle. Participants may continue treatment until disease progression or another reason for discontinuation occurs. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Objective Response Rate (ORR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0 assessed by Blinded Independent Central Review (BICR)
Tidsram: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
ORR defined as the proportion of participants with the confirmed best overall response of Complete Response (CR), Partial Response (PR) or Minor Response (MR) per modified RANO 2.0, assessed by BICR |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
ORR per modified RANO 2.0 assessed by Investigator
Tidsram: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
ORR defined as the proportion of participants with the confirmed best overall response of CR, PR or MR per modified RANO 2.0, assessed by the Investigator |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
|
Volumetric Tumor Growth Rate (TGR) by BICR
Tidsram: From historical scans through the final scan in the study, approximately 18 months
|
TGR defined as the percentage change in tumor volume by unit of time, assessed by BICR |
From historical scans through the final scan in the study, approximately 18 months
|
|
Duration of Response (DOR) per modified RANO 2.0 assessed by BICR and by Investigator
Tidsram: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
DOR, time from the first documentation of objective response (CR, PR, or MR) to the date of the first occurrence of radiographic disease progression per modified RANO 2.0 assessed by BICR and by the Investigator or death from any cause, whichever occurs earlier. |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
|
Time to Next Intervention (TTNI)
Tidsram: From the date of first dose of study drug until the date of the start of another anticancer treatment or date of death, approximately 18 months
|
TTNI, defined as the time from the first dose of study drug to the initiation of first subsequent anticancer therapy or death from any cause, whichever occurs earlier |
From the date of first dose of study drug until the date of the start of another anticancer treatment or date of death, approximately 18 months
|
|
Progression Free Survival (PFS) per modified RANO 2.0 assessed by BICR and by Investigator
Tidsram: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
PFS, defined as the time from the first dose of study drug to the date of the first occurrence of radiographic disease progression per modified RANO 2.0 assessed by BICR and by the Investigator or death from any cause, whichever occurs earlier. |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
|
Time to Response (TTR) per modified RANO 2.0 assessed by BICR and by Investigator
Tidsram: From the date of first dose of study drug to the first documentation of objective response (CR, PR, or MR), approximately 18 months
|
TTR, defined as the time from the first dose of study drug to the first documentation of objective response (CR, PR, or MR) per modified RANO 2.0, assessed by BICR and by the Investigator |
From the date of first dose of study drug to the first documentation of objective response (CR, PR, or MR), approximately 18 months
|
|
Overall Survival (OS)
Tidsram: From the date of first dose of study drug until the date of death, approximately 18 months
|
OS, defined as the time from the first dose of study drug to death from any cause. |
From the date of first dose of study drug until the date of death, approximately 18 months
|
|
Safety and tolerability
Tidsram: From the date of first dose of study drug until 30 days after the date of the last dose of study drug, approximately 18 months
|
The safety and tolerability of safusidenib evaluated based on AEs graded by NCI-CTCAE version 5.0, laboratory abnormalities as graded by NCI-CTCAE version 5.0, vital signs, physical examinations, and ECGs |
From the date of first dose of study drug until 30 days after the date of the last dose of study drug, approximately 18 months
|
|
Seizure Activity
Tidsram: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
Evaluate seizure frequencies and severity including type of seizure, seizure-related AEs, and changes in anti-epileptic medications in participants receiving safusidenib |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- NUV-218-G209
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .